TXNDC17

Across TCGA pan-cancer cohorts, TXNDC17 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TXNDC17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TXNDC17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TXNDC17 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where TXNDC17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TXNDC17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+1.193	<.001	9	view →
LSCC	Female	All	+0.395	<.001	8	view →
CCRCC	Male	All	−0.251	<.001	8	view →
HNSC	Male	All	−0.181	.009	4	view →
OV	All	All	+0.510	.004	2	view →
PDAC	Male	All	+0.224	.048	1	view →
COAD	All	IV	−0.203	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TXNDC17–LUAD

Open the LUAD breakdown →